BRUSSELS, Dec 1 (Reuters) - Innogenetics (INNX.BR: Quote, Profile, Research) said on Thursday it had ended prematurely a distribution agreement with Abbott Laboratories (ABT.N: Quote, Profile, Research) for transplant organ test kits because it could make more money selling the kits itself.
